Preclinical pharmacokinetics, antitumor activity and single ascending dose tolerability of GBO-006 nanosuspension, a selective polo-like kinase 2 (PLK2) inhibitor.

Autor:	Maddi, Srinivas1 srinivasarao.maddi@gvkbio.com, Lenkalepally, Srinivas1, Srivastava, Pratima1, Jeyaraj, Duraiswamy A.1, Chowdhury, Arnab Roy1, Rajagopalan, Lakshman1, Gupta, Jang B.1
Zdroj:	Drug Invention Today. Jan2018, Vol. 10 Issue 1, p14-22. 9p. 5 Charts, 7 Graphs.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu